<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29167644</article-id><article-id pub-id-type="pmc">5682333</article-id><article-id pub-id-type="doi">10.3389/fphar.2017.00814</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kraehenmann</surname><given-names>Rainer</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/332666/overview"/></contrib><contrib contrib-type="author"><name><surname>Pokorny</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/149989/overview"/></contrib><contrib contrib-type="author"><name><surname>Aicher</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Preller</surname><given-names>Katrin H.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/94346/overview"/></contrib><contrib contrib-type="author"><name><surname>Pokorny</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bosch</surname><given-names>Oliver G.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/244400/overview"/></contrib><contrib contrib-type="author"><name><surname>Seifritz</surname><given-names>Erich</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/69053/overview"/></contrib><contrib contrib-type="author"><name><surname>Vollenweider</surname><given-names>Franz X.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>, <addr-line>Z&#x000fc;rich</addr-line>, <country>Switzerland</country></aff><aff id="aff2"><sup>2</sup><institution>Neuropsychopharmacology and Brain Imaging Unit, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich</institution>, <addr-line>Z&#x000fc;rich</addr-line>, <country>Switzerland</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Psychosomatic Medicine and Psychotherapy, University of Ulm</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: <italic>Rick Strassman, University of New Mexico School of Medicine, United States</italic></p></fn><fn fn-type="edited-by"><p>Reviewed by: <italic>Tomiki Sumiyoshi, National Center of Neurology and Psychiatry, Japan; Mendel Kaelen, Imperial College London, United Kingdom</italic></p></fn><corresp id="fn001">*Correspondence: <italic>Rainer Kraehenmann, <email xlink:type="simple">r.kraehenmann@bli.uzh.ch</email></italic></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>814</elocation-id><history><date date-type="received"><day>11</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Kraehenmann, Pokorny, Aicher, Preller, Pokorny, Bosch, Seifritz and Vollenweider.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Kraehenmann, Pokorny, Aicher, Preller, Pokorny, Bosch, Seifritz and Vollenweider</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Rationale:</bold> Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking &#x02013; an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces primary process thinking under placebo-controlled, standardized experimental conditions and whether these effects are related to subjective experience and 5-HT2A receptor activation. Therefore, this study aimed to test the hypotheses that LSD increases primary process thinking and that primary process thinking depends on 5-HT2A receptor activation and is related to subjective drug effects.</p><p><bold>Methods:</bold> Twenty-five healthy subjects performed an audio-recorded mental imagery task 7 h after drug administration during three drug conditions: placebo, LSD (100 mcg orally) and LSD together with the 5-HT2A receptor antagonist ketanserin (40 mg orally). The main outcome variable in this study was primary index (PI), a formal measure of primary process thinking in the imagery reports. State of consciousness was evaluated using the Altered State of Consciousness (5D-ASC) rating scale.</p><p><bold>Results:</bold> LSD, compared with placebo, significantly increased primary index (<italic>p</italic> &#x0003c; 0.001, Bonferroni-corrected). The LSD-induced increase in primary index was positively correlated with LSD-induced disembodiment (<italic>p</italic> &#x0003c; 0.05, Bonferroni-corrected), and blissful state (<italic>p</italic> &#x0003c; 0.05, Bonferroni-corrected) on the 5D-ASC. Both LSD-induced increases in primary index and changes in state of consciousness were fully blocked by ketanserin.</p><p><bold>Conclusion:</bold> LSD induces primary process thinking via activation of 5-HT2A receptors and in relation to disembodiment and blissful state. Primary process thinking appears to crucially organize inner experiences during both dreams and psychedelic states of consciousness.</p></abstract><kwd-group><kwd>LSD</kwd><kwd>ketanserin</kwd><kwd>5-HT2A receptor</kwd><kwd>mental imagery</kwd><kwd>primary and secondary process thinking</kwd><kwd>primary emotions</kwd><kwd>cognitive bizarreness</kwd><kwd>healthy subjects</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="58"/><page-count count="9"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p>There is now accumulating evidence (<xref rid="B46" ref-type="bibr">Sloman and Steinberg, 1996</xref>; <xref rid="B12" ref-type="bibr">Evans, 2008</xref>; <xref rid="B44" ref-type="bibr">Shanks, 2010</xref>) confirming and extending the early meta-psychological theory of Freud (<xref rid="B42" ref-type="bibr">Pribram and Gill, 1976</xref>) which posits that there exist two distinct modes of psychic functioning: primary process and secondary process. It is broadly believed that in normal adults, secondary process is a hierarchically higher-level cognitive mode which fulfills an adaptive, reflective, rule-bound function (&#x0201c;reality principle&#x0201d; in Freudian terms) and thus inhibits lower-level, automatic, motivation- and emotion-driven primary process (&#x0201c;pleasure principle&#x0201d; in Freudian terms) (<xref rid="B1" ref-type="bibr">Arminjon, 2011</xref>). Under altered psychophysiological conditions such as dreaming, hypnosis, meditation, sensory deprivation, respiratory maneuvers, trance, psychosis, and epilepsy, primary process may become the prevailing cognitive mode (<xref rid="B3" ref-type="bibr">Barr et al., 1972</xref>; <xref rid="B54" ref-type="bibr">Vaitl et al., 2005</xref>; <xref rid="B18" ref-type="bibr">Hermle and Kraehenmann, 2017</xref>). Primary process thinking can be operationalized and reliably assessed using formal linguistic measures such as image fusion; unlikely combinations or events; sudden shifts or transformations of images; and contradictory or illogical actions, feelings, or thoughts (<xref rid="B43" ref-type="bibr">Rapaport, 1950</xref>; <xref rid="B19" ref-type="bibr">Holt, 1956</xref>; <xref rid="B2" ref-type="bibr">Auld et al., 1968</xref>; <xref rid="B45" ref-type="bibr">Shevrin, 1996</xref>; <xref rid="B46" ref-type="bibr">Sloman and Steinberg, 1996</xref>; <xref rid="B6" ref-type="bibr">Brakel et al., 2000</xref>).</p><p>Previous studies (<xref rid="B28" ref-type="bibr">Landon and Fischer, 1970</xref>; <xref rid="B34" ref-type="bibr">Martindale and Fischer, 1977</xref>; <xref rid="B36" ref-type="bibr">Natale et al., 1978</xref>; <xref rid="B49" ref-type="bibr">Spitzer et al., 1996</xref>; <xref rid="B13" ref-type="bibr">Family et al., 2016</xref>; <xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>) indicate that classical psychedelics such as lysergic acid diethylamide (LSD) and related compounds such as psilocybin activate mental processes which are closely related to primary process, such as vivid, dreamlike imagery, basic emotions, and bizarre thinking. For example, early linguistic studies (<xref rid="B28" ref-type="bibr">Landon and Fischer, 1970</xref>; <xref rid="B34" ref-type="bibr">Martindale and Fischer, 1977</xref>; <xref rid="B36" ref-type="bibr">Natale et al., 1978</xref>) investigated the effects of psychedelics on thought content using primary process dictionaries. They found that psychedelics acutely increase frequency of primary process words in subjective reports of healthy subjects. Moreover, recent studies (<xref rid="B49" ref-type="bibr">Spitzer et al., 1996</xref>; <xref rid="B13" ref-type="bibr">Family et al., 2016</xref>) showed that psychedelics enhance access to remote and non-obvious associations in tasks where subjects have to rely on automatic, intuitive and uncontrolled thinking. Finally, we (<xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>) recently investigated the effects of LSD on imagery reports of healthy subjects. We found that LSD increased cognitive bizarreness, a formal measure of dreaming cognition, via activation of the serotonin 2A (5-HT2A) receptor. Taken together, previous research on the effects of psychedelics on thought processes indicate that psychedelics may shift cognition toward primary process thinking.</p><p>However, it is still largely unknown whether LSD induces primary process thinking under placebo-controlled, standardized experimental conditions, and whether these effects are related to subjective experience and 5-HT2A receptor activation. A better understanding of the cognitive mechanisms underlying psychedelic states of consciousness is important, especially given that there is accumulating qualitative evidence (<xref rid="B15" ref-type="bibr">Gasser et al., 2015</xref>; <xref rid="B5" ref-type="bibr">Belser et al., 2017</xref>; <xref rid="B57" ref-type="bibr">Watts et al., 2017</xref>) indicating that the therapeutic effects of psychedelics may be mediated by their acute effects on subjective experience. Therefore, in this study, we compared the post-peak effects of LSD, placebo and LSD after pre-treatment with the 5-HT2A receptor antagonist ketanserin on primary process thinking in mental imagery reports of healthy subjects. Primary index (PI), a formal measure of primary process thinking (<xref rid="B50" ref-type="bibr">Stigler, 2001</xref>; <xref rid="B14" ref-type="bibr">Frick et al., 2008</xref>), was used as primary endpoint in this study. We hypothesized that LSD would increase PI in verbal imagery reports. We further hypothesized that ketanserin would block the effects of LSD on PI and subjective experience. Finally, given the relative novelty of the primary endpoint variable (PI) in the field of cognitive neuroscience, we performed multiple correlation analyses to quantitatively assess the relationship between PI and other more common measures which had been frequently used to assess psychedelic-induced changes in state of consciousness, using a short version of the Altered State of Consciousness (5D-ASC) self-rating scale; ratings of mental imagery experience, using visual analog scales (VASs); and dreaming cognition, using cognitive bizarreness (BD) in the mental imagery reports.</p></sec><sec sec-type="materials|methods" id="s1"><title>Materials and Methods</title><sec><title>Study Design</title><p>The study followed a double-blind, placebo-controlled, within-subjects, crossover design that involved three experimental sessions in balanced order. The washout periods between sessions were at least 14 days. This study was carried out in accordance with the recommendations of the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice (ICH-GCP). All subjects gave written informed consent. The protocol was approved by the Cantonal Ethics Committee of Zurich. The administration of LSD in healthy subjects was authorized by the Swiss Federal Office for Public Health, Bern, Switzerland.</p></sec><sec><title>Participants</title><p>Twenty-five healthy subjects (19 men, 6 women; mean age &#x000b1; SD: 25 &#x000b1; 4 years; range: 20&#x02013;34 years) participated in the study. Subjects had to be physically and mentally healthy. Exclusion criteria were pregnancy, poor knowledge of the German language, history of alcohol or illicit drug dependence, and previous significant adverse reaction to a psychedelic drug. Nine of the 25 subjects had prior experience with classic psychedelics (number of subjects: psilocybin 6, LSD 3, LSA<sup>1</sup> 1, DMT<sup>2</sup> 1, 2C-E<sup>3</sup> 1).</p></sec><sec><title>Study Procedures</title><p>The mental imagery task from this study has been described in detail elsewhere (<xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>). Briefly, the 30-min task followed the mental imagery method developed by <xref rid="B30" ref-type="bibr">Leuner (1969)</xref> and was performed 7 h after drug treatment, during the descending phase of the acute effects of LSD (<xref rid="B10" ref-type="bibr">Dolder et al., 2015</xref>). The task was conducted in an esthetic living-room-like room located in a tranquil side wing of the research department. Mental imagery reports from the subjects were audio recorded and transcribed for statistical analysis.</p></sec><sec><title>Study Drug</title><p>In each of the three experimental sessions, subjects first received pre-treatment, followed by treatment after 1 h. The drug conditions were LSD (placebo + 100 mcg LSD orally), Ket+LSD (40 mg ketanserin + 100 mcg LSD orally), and Pla (placebo + placebo orally).</p></sec></sec><sec><title>Measures</title><sec><title>State of Consciousness and Mental Imagery Experience</title><p>Subjective state of consciousness at the time of the mental imagery task (390 min after drug intake) was evaluated using a short version of the Altered State of Consciousness (5D-ASC) rating scale (<xref rid="B52" ref-type="bibr">Studerus et al., 2010</xref>) for spiritual experience, blissful state, disembodiment, elementary imagery, and changed meaning of percepts. Mental imagery experience was evaluated using visual analog subscales (VASs) for visual vividness, emotional arousal, positive emotions, negative emotions, insight and relaxation.</p><p>To assess the relationship between primary process thinking and dream mentation, we included cognitive bizarreness (BD) in the multiple correlations analysis of this study (cognitive bizarreness is a standardized formal measure of dream mentation and had been calculated from the mental imagery reports of this study sample (<italic>N</italic> = 25) elsewhere, see <xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>).</p></sec><sec><title>Primary and Secondary Process Thinking</title><p>The main outcome measure in this study was primary index (PI), a formal measure of primary process thinking which had been previously used in text-analytical studies on primary process thinking and mental imagery (<xref rid="B50" ref-type="bibr">Stigler, 2001</xref>; <xref rid="B14" ref-type="bibr">Frick et al., 2008</xref>). PI was calculated by dividing the relative frequency of primary process (PP) scores by the sum of primary process and secondary process (SP) scores in the imagery reports (PI = 100 &#x000d7; PP/(PP+SP)) (<xref rid="B50" ref-type="bibr">Stigler, 2001</xref>). The relative frequency of PP and SP scores was calculated by dividing the PP and SP scores by the number of words in the reports.</p><p>Primary process was evaluated using the rating scale of <xref rid="B2" ref-type="bibr">Auld et al. (1968)</xref>, a comprehensive scale for measuring primary process thinking. The scale consists of nine PP categories (condensation, unlikely combinations or events, fluid transformations, visual representation, symbolism, contradiction, magic occurrences, inhibited movement, taboo sexual and aggressive acts) which sum up to the PP score. Examples for PP items from our study subjects: &#x0201c;&#x02026;a cat is coming from the right side. The cat has huge blue and luminous eyes&#x02026;the eyes look upward, then down, left, right, always alternating, like a cuckoo clock with moving eyes&#x02026;now she has turned into a wooden clock hanging on a wall&#x0201d;; &#x0201c;I am part of a metal plate&#x02026;I am fusing with the metal plate&#x02026;I am now a part of this plate&#x02026;it feels like being a liquid&#x02026;I am only existing in certain parts of my body&#x02026;The whole room rolls itself and suddenly, everything is dark&#x02026;I can only see flickering light and two-dimensional faces&#x0201d;; &#x0201c;I see two entangled persons, like an art painting&#x02026;when I approach the two persons, they form an ugly bulb and dissolve into bubbles&#x02026;now I see a huge mouth with yellow teeth&#x02026;the mouth snaps and draws everything in.&#x0201d;</p><p>Secondary process was evaluated using a modified version (<xref rid="B37" ref-type="bibr">Natale et al., 1979</xref>) of the rating scale of <xref rid="B58" ref-type="bibr">Weintraub and Aronson (1969)</xref>, a comprehensive scale for measuring secondary process thinking. The scale consists of seven SP categories (non-personal reference, negators, qualifiers, retractors, explaining, expressions of feeling, evaluators) which sum up to the SP score. Examples for SP items from our study subjects: &#x0201c;&#x02026;the room has got a bed. The bed is covered with a blanket protecting the bed from dust, I suppose. The bed is adorned with two or three carefully arranged pillows - this looks beautiful&#x02026;&#x0201d;; &#x0201c;It is a little brook with trees along the banks&#x02026;actually, the water is really cold&#x02026;it feels good&#x02026;the water is indeed cold as ice and it is freezing, but because I only dip my feet in the water, it is an extremely good feeling, vitalizing&#x02026;&#x0201d;; &#x0201c;&#x02026;it is not such a special house&#x02026;it has a roof, a balcony, windows, a garden&#x02026;in front of the house there is scrub, plants&#x02026;and a green meadow&#x02026;the meadow is not so beautiful, doesn&#x02019;t look quite as well cared for as it should&#x02026;&#x0201d;.</p></sec></sec><sec><title>Statistics</title><p>The statistical analyses were performed using IBM SPSS Statistics 23 software (IBM, Chicago, IL, United States). Repeated-measures analyses of variance (ANOVAs) were conducted to compare the drug effects in LSD, Ket+LSD, and Pla conditions. Significant main effects or interactions in the ANOVAs were followed by Bonferroni-corrected <italic>post hoc</italic> pairwise comparisons with a significance level of <italic>p</italic> &#x0003c; 0.05 (two-tailed test). Bonferroni-corrected Spearman multiple correlations (Bonferroni-corrected alpha = 0.05/12 = 0.0042) were used to quantify the relations between the LSD-Pla difference scores for primary index (&#x00394;PI), state of consciousness (&#x00394;5D-ASC), mental imagery experience (&#x00394;VAS), and cognitive bizarreness (&#x00394;BD).</p></sec><sec><title>Results</title><sec><title>State of Consciousness and Mental Imagery Experience</title><p>Lysergic acid diethylamide significantly changed state of consciousness, as indicated by a significant main effect of drug [<italic>F</italic>(2,48) = 89.42, <italic>p</italic> &#x0003c; 0.001, <inline-formula><mml:math id="M1"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.79) in a repeated-measures (drug &#x000d7; subscale) ANOVA on 5D-ASC score at T3. There was also a significant main effect of subscale [<italic>F</italic>(4,96) = 17.63, <italic>p</italic> &#x0003c; 0.001, <inline-formula><mml:math id="M2"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.42] and a significant drug &#x000d7; subscale interaction [<italic>F</italic>(8,192) = 16.01, <italic>p</italic> &#x0003c; 0.001, <inline-formula><mml:math id="M3"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.40]. Bonferroni-corrected <italic>post hoc</italic> pairwise comparisons revealed a greater score on all five 5D-ASC subscales in the LSD condition than in the Pla and Ket+LSD conditions (all <italic>p</italic> &#x0003c; 0.05). Scores did not differ between the Pla and Ket+LSD conditions for any 5D-ASC subscale (all <italic>p</italic> = n.s.), indicating that ketanserin pre-treatment completely blocked all LSD-induced effects (<bold>Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref></bold>).</p><p>Lysergic acid diethylamide significantly changed subjective mental imagery experience, as indicated by a significant main effect of drug [F(2,48) = 8.57, p &#x0003c; 0.001, <inline-formula><mml:math id="M4"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.26] in a repeated-measures (drug &#x000d7; subscale) ANOVA on the retrospectively administered VAS for mental imagery experience. There was also a significant main effect of subscale [F(2.86,68.71) = 55.23, p &#x0003c; 0.001, <inline-formula><mml:math id="M5"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.70] and a significant drug &#x000d7; subscale interaction [F(5.58, 133.86) = 3.21, p = 0.007, <inline-formula><mml:math id="M6"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.12]. Bonferroni-corrected <italic>post hoc</italic> pairwise comparisons revealed greater VAS score on the vividness and emotional arousal subscales in the LSD condition than in the Pla condition and on the vividness subscale in the LSD condition than in the Ket+LSD condition (all p &#x0003c; 0.05). VAS score did not differ between the Pla and Ket+LSD conditions for any VAS subscale (all p = n.s.), indicating that ketanserin pre-treatment completely blocked all LSD-induced effects (<bold>Supplementary Figure <xref ref-type="supplementary-material" rid="SM2">S2</xref></bold>).</p></sec><sec><title>Primary and Secondary Process Thinking</title><p>Lysergic acid diethylamide significantly increased primary process thinking, as indicated by a significant main effect of drug [<italic>F</italic>(1.07,25.70) = 50.63, <italic>p</italic> &#x0003c; 0.001, <inline-formula><mml:math id="M7"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.6] in a one-way repeated-measures ANOVA on PI; and Bonferroni-corrected <italic>post hoc</italic> comparisons revealing significantly greater PI in the LSD condition than in the Pla and Ket+LSD conditions (all <italic>p</italic> &#x0003c; 0.001). PI did not differ between the Pla and Ket+LSD conditions (<italic>p</italic> = 0.07), indicating that ketanserin pre-treatment completely blocked the effect of LSD on PI (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Furthermore, the LSD-induced increase in PI was driven by an increase in PP, and not by a decrease in SP, as indicated by a significant drug &#x000d7; category (PP, SP) interaction [<italic>F</italic>(1.54,36.87) = 13.30, <italic>p</italic> &#x0003c; 0.001, <inline-formula><mml:math id="M8"><mml:msubsup><mml:mi mathvariant="normal" mathcolor="black">&#x003b7;</mml:mi><mml:mi mathvariant="normal" mathcolor="black">p</mml:mi><mml:mn mathvariant="normal" mathcolor="black">2</mml:mn></mml:msubsup></mml:math></inline-formula> = 0.32] in a separate repeated-measures ANOVA; and Bonferroni-corrected <italic>post hoc</italic> pairwise comparisons revealing greater PP, but unchanged SP, in the LSD condition than in the Pla and Ket+LSD conditions (all <italic>p</italic> &#x0003c; 0.001). PP did not differ between the Pla and Ket+LSD conditions (all <italic>p</italic> = n.s.), indicating that ketanserin pre-treatment completely blocked the effect of LSD on PP (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Relative frequencies and <italic>post hoc</italic> pairwise comparisons for primary process, secondary process, and primary index in the three drug conditions.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" colspan="3" rowspan="1">Relative frequency<sup>g</sup><hr/></th><th valign="top" align="center" colspan="3" rowspan="1"><italic>t<sub>24</sub></italic> value<sup>h</sup>
<italic>p</italic>-value<sup>i</sup><hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Category</th><th valign="top" align="center" rowspan="1" colspan="1">Pla<sup>d</sup></th><th valign="top" align="center" rowspan="1" colspan="1">Ket+LSD<sup>e</sup></th><th valign="top" align="center" rowspan="1" colspan="1">LSD<sup>f</sup></th><th valign="top" align="center" rowspan="1" colspan="1">LSD &#x0003e; Pla</th><th valign="top" align="center" rowspan="1" colspan="1">LSD &#x0003e; Ket+LSD</th><th valign="top" align="center" rowspan="1" colspan="1">Ket+LSD &#x0003e; Pla</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">PP<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.0007</td><td valign="top" align="center" rowspan="1" colspan="1">0.0012</td><td valign="top" align="center" rowspan="1" colspan="1">0.0080</td><td valign="top" align="center" rowspan="1" colspan="1">6.40</td><td valign="top" align="center" rowspan="1" colspan="1">6.42</td><td valign="top" align="center" rowspan="1" colspan="1">1.86</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">(0.0013)</td><td valign="top" align="center" rowspan="1" colspan="1">(0.0022)</td><td valign="top" align="center" rowspan="1" colspan="1">(0.0063)</td><td valign="top" align="center" rowspan="1" colspan="1">0.000001<sup>&#x02217;&#x02217;</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.000001<sup>&#x02217;&#x02217;</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SP<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.0451</td><td valign="top" align="center" rowspan="1" colspan="1">0.0459</td><td valign="top" align="center" rowspan="1" colspan="1">0.0427</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;0.97</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;1.80</td><td valign="top" align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">(0.0128)</td><td valign="top" align="center" rowspan="1" colspan="1">(0.0105)</td><td valign="top" align="center" rowspan="1" colspan="1">(0.0110)</td><td valign="top" align="center" rowspan="1" colspan="1">0.34</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td><td valign="top" align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PI<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">1.3375</td><td valign="top" align="center" rowspan="1" colspan="1">2.3237</td><td valign="top" align="center" rowspan="1" colspan="1">14.7980</td><td valign="top" align="center" rowspan="1" colspan="1">7.26</td><td valign="top" align="center" rowspan="1" colspan="1">7.12</td><td valign="top" align="center" rowspan="1" colspan="1">2.44</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">(1.9622)</td><td valign="top" align="center" rowspan="1" colspan="1">(3.2501)</td><td valign="top" align="center" rowspan="1" colspan="1">(9.9916)</td><td valign="top" align="center" rowspan="1" colspan="1">0.0000002<sup>&#x02217;&#x02217;</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.0000002<sup>&#x02217;&#x02217;</sup></td><td valign="top" align="center" rowspan="1" colspan="1">0.02</td></tr></tbody></table><table-wrap-foot><attrib><italic>N = 25. <sup>a</sup>Primary process. <sup>b</sup>Secondary process. <sup>c</sup>Primary index, 100 &#x000d7; PP/(PP+SP). <sup>d</sup>Placebo. <sup>e</sup>Ketanserin. <sup>f</sup>Lysergic acid diethylamide. <sup>g</sup>Mean (SD). <sup>h</sup><italic>Post hoc</italic> paired <italic>t</italic> tests, two-tailed. <sup>i</sup>Uncorrected <italic>p</italic>-value. <sup>&#x02217;</sup>p &#x0003c; 0.05, Bonferroni-corrected; <sup>&#x02217;&#x02217;</sup>p &#x0003c; 0.001, Bonferroni-corrected (alpha threshold 0.05/9 = 0.0056).</italic></attrib><attrib><italic><sup>1</sup><italic>D</italic>-lysergic acid amide.</italic></attrib><attrib><italic><sup>2</sup><italic>N,N</italic>-dimethyltryptamine.</italic></attrib><attrib><italic><sup>3</sup>2,5-dimethoxy-4-ethylphenethylamine.</italic></attrib></table-wrap-foot></table-wrap></sec><sec><title>Relations between Outcome Variables</title><p>There was a significant positive correlation between LSD-induced change (LSD-Pla difference score) in PI and LSD-induced change in 5D-ASC scores for the disembodiment subscale (<italic>r</italic> = 0.61, <italic>N</italic> = 25, <italic>p</italic> = 0.012, Bonferroni-corrected) and for the blissful state subscale (<italic>r</italic> = 0.63, <italic>N</italic> = 25, <italic>p</italic> = 0.012, Bonferroni-corrected) (<bold>Figures <xref ref-type="fig" rid="F1">1A,B</xref></bold>). Furthermore, there was a highly significant positive correlation between LSD-induced change in PI and LSD-induced change in BD (<italic>r</italic> = 0.89, <italic>N</italic> = 25, <italic>p</italic> &#x0003c; 0.001, Bonferroni-corrected) (<bold>Figure <xref ref-type="fig" rid="F1">1C</xref></bold>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p><bold>(A)</bold> Change in disembodiment was related to change in primary index of mental imagery reports. The scatter plot shows the relation between the LSD-induced increase in score on the disembodiment subscale of the 5D-ASC (difference between LSD and placebo drug conditions, <italic>x</italic>-axis) and the LSD-induced increase in primary index score of mental imagery reports (difference between LSD and placebo drug conditions, <italic>y</italic>-axis) (<italic>r</italic> = 0.61, <italic>N</italic> = 25, <italic>p</italic> = 0.012, Bonferroni-corrected); <bold>(B)</bold> Change in blissful state was related to change in primary index of mental imagery reports. The scatter plot shows the relation between the LSD-induced increase in score on blissful state subscale of the 5D-ASC (difference between LSD and placebo drug conditions, <italic>x</italic>-axis) and the LSD-induced increase in primary index score of mental imagery reports (difference between LSD and placebo drug conditions, <italic>y</italic>-axis) (<italic>r</italic> = 0.63, <italic>N</italic> = 25, <italic>p</italic> = 0.012, Bonferroni-corrected); <bold>(C)</bold> Change in cognitive bizarreness was related to change in primary index of mental imagery reports. The scatter plot shows the relation between the LSD-induced increase in cognitive bizarreness score (difference between LSD and placebo drug conditions, <italic>x</italic>-axis) and the LSD-induced increase in primary index score of mental imagery reports (difference between LSD and placebo drug conditions, <italic>y</italic>-axis) (<italic>r</italic> = 0.89, <italic>N</italic> = 25, <italic>p</italic> &#x0003c; 0.001, Bonferroni-corrected). Pla, placebo; LSD, lysergic acid diethylamide.</p></caption><graphic xlink:href="fphar-08-00814-g001"/></fig></sec></sec><sec><title>Discussion</title><p>The main finding of this study was that LSD increased primary process thinking, a lower-level, automatic, motivation- and emotion-driven mode of mental organization which is characterized by image fusion; unlikely combinations or events; sudden shifts or transformations of images; and contradictory or illogical actions, feelings, or thoughts (<xref rid="B43" ref-type="bibr">Rapaport, 1950</xref>; <xref rid="B19" ref-type="bibr">Holt, 1956</xref>; <xref rid="B2" ref-type="bibr">Auld et al., 1968</xref>; <xref rid="B45" ref-type="bibr">Shevrin, 1996</xref>; <xref rid="B46" ref-type="bibr">Sloman and Steinberg, 1996</xref>; <xref rid="B6" ref-type="bibr">Brakel et al., 2000</xref>). Specifically, we show that LSD, in comparison with placebo, increased primary index, a formal linguistic measure of primary process thinking in the imagery reports (<xref rid="B2" ref-type="bibr">Auld et al., 1968</xref>; <xref rid="B50" ref-type="bibr">Stigler, 2001</xref>) (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Furthermore, we found that the effect of LSD on primary index was completely blocked by ketanserin, a 5-HT2A receptor antagonist (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). Finally, we show that the LSD-induced increase in primary index was related to LSD-induced disembodiment and blissful state (<bold>Figures <xref ref-type="fig" rid="F1">1A,B</xref></bold>).</p><p>Our finding that LSD acutely increased primary process thinking is supported by both direct and indirect evidence: <xref rid="B28" ref-type="bibr">Landon and Fischer (1970)</xref>, for example, assessed the effects of low-dose (0.08 mg/kg orally) psilocybin on several linguistic parameters. It was found that psilocybin decreased sentence length and syntactic and rhetorical complexity, but increased linguistic concreteness and stereotypy, consistent with primary process thinking. Furthermore, <xref rid="B34" ref-type="bibr">Martindale and Fischer (1977)</xref> used content-analytic measures to directly test the hypothesis that psilocybin (0.08&#x02013;0.2 mg/kg) induces primary process thinking. They showed that psilocybin increased primary process words, particularly content related to regressive imagery. Moreover, <xref rid="B36" ref-type="bibr">Natale et al. (1978</xref>, <xref rid="B37" ref-type="bibr">1979</xref>) investigated the effects of low to medium dose LSD (15&#x02013;100 mcg) on speech patterns of depressed patients during psychoanalytic sessions. They found that LSD increased the patients&#x02019; use of novel figurative language and of primary process-related words, respectively, consistent with an increase in primary process thinking. Furthermore, <xref rid="B3" ref-type="bibr">Barr et al. (1972)</xref> and <xref rid="B20" ref-type="bibr">Holt (2002)</xref> investigated the effects of LSD on primary process responses to the Rorschach projective test. They found highly significant LSD effects on formal measures of primary process thinking, including features such as image fusion, fluid transformations of percepts, autistic logic, logical contradictions, verbal condensations, loosening of memory, and unlikely combinations. Finally, recent double-blind, placebo-controlled studies lend further support to the notion that psychedelics enhance primary process thinking: <xref rid="B49" ref-type="bibr">Spitzer et al. (1996)</xref> for example, used word-pairs of different semantic distance and showed that psilocybin increased indirect semantic priming, i.e., priming for remotely related word-pairs. Interestingly, the authors interpreted their results as evidence that psilocybin &#x0201c;in fact leads to an increased availability of remote associations and thereby may bring cognitive contents to mind that under normal circumstances remain non-activated.&#x0201d; Similar effects were found for LSD in a recent double-blind, placebo-controlled study by <xref rid="B13" ref-type="bibr">Family et al. (2016)</xref>. Taken together, both our results and previous evidence indicate that psychedelics induce an altered state of consciousness which is characterized by primary process cognition. Our findings are also in line with recent neuroimaging data: the entropic brain theory (<xref rid="B9" ref-type="bibr">Carhart-Harris et al., 2014</xref>), for example, holds that secondary process (the cognitive mode of the Freudian &#x0201c;ego&#x0201d;) is coded by default mode network (DMN) regions and provides top&#x02013;down predictions to reduce free-energy associated with the primary process (the Freudian &#x0201c;id&#x0201d;) within (para)limbic and anti-correlated neural networks, converting free energy into bound energy. According to the entropic brain theory, psychedelics induce an &#x0201c;unconstrained,&#x0201d; &#x0201c;high-entropy&#x0201d; cognitive state whereby DMN activity breaks down, leading to broadband alterations in resting-state functional connectivity between regions that show little connectivity in a baseline state.</p><p>However, contrary to such cognitive shift models, which posit that psychedelics decrease secondary process thinking, leading to disinhibition of primary process thinking (&#x0201c;ego regression,&#x0201d; in psychoanalytical terms), our data did not show a statistically significant effect of LSD on SP, while there was a significant increase in PP during LSD compared to placebo (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>). These findings seem to suggest that there is no simple &#x0201c;shift&#x0201d; or &#x0201c;transition&#x0201d; from secondary toward primary process thinking during psychedelic states: secondary process thinking during psychedelic states appears preserved, while there is an increase in primary process thinking. This may be an important feature distinguishing night dreams from psychedelic experiences. In fact, a recent neuroimaging study (<xref rid="B32" ref-type="bibr">Lewis et al., 2017</xref>) showed that psychedelics increase rather than decrease neural activity in cortical areas that are thought to mediate the features of secondary process thinking, including dorsolateral prefrontal cortex (DLPFC) and temporal cortex (<xref rid="B11" ref-type="bibr">Dresler et al., 2014</xref>). Therefore, psychedelic states may be best conceptualized as hybrid states of consciousness which share features of both dreaming and waking consciousness. This is supported by a recent neuroimaging study (<xref rid="B56" ref-type="bibr">Voss et al., 2014</xref>) which showed that dreaming (and hence unaware) subjects regained self-awareness in their dreams (they became &#x0201c;lucid&#x0201d;) following frontal low current stimulation of gamma activity over DLPFC regions. In fact, the close neurophenomenological similarity between psychedelic states and lucid dreaming (<xref rid="B24" ref-type="bibr">Kraehenmann, 2017</xref>) may shed some light on the therapeutic potential of psychedelic-induced experiences: they are not just &#x0201c;epiphenomena&#x0201d; of underlying neuronal oscillations, but rather induce conscious learning experiences that promote self-knowledge and psychological insight.</p><p>The human brain is a hierarchically organized and evolutionally layered organ, and this basic structure is reflected in the cognitive organization of the mind (<xref rid="B35" ref-type="bibr">Montag and Panksepp, 2017</xref>). Primary process thinking has been related to neuronal activation of ontologically early, subcortical and limbic regions of the brain which code for instinctual drives and primal affective experiences (<xref rid="B48" ref-type="bibr">Solms and Panksepp, 2012</xref>; <xref rid="B35" ref-type="bibr">Montag and Panksepp, 2017</xref>). In addition, previous neuroimaging studies (<xref rid="B8" ref-type="bibr">Carhart-Harris et al., 2012</xref>; <xref rid="B26" ref-type="bibr">Kraehenmann et al., 2015</xref>, <xref rid="B27" ref-type="bibr">2016</xref>; <xref rid="B32" ref-type="bibr">Lewis et al., 2017</xref>) indicate that psychedelics such as psilocybin modulate information processing in both cortical and subcortical memory and emotion circuits of the brain (e.g., cingulate cortex, temporal cortex, insula, amygdala, hippocampus). This is supported by recent receptor binding studies showing a dense and widespread expression of 5-HT2A/5-HT1A receptors in both cortical and subcortical areas of the human brain (<xref rid="B4" ref-type="bibr">Beliveau et al., 2017</xref>). This may explain why, in psychedelic states, basic drives and primary emotions are strongly activated and substantially influence cognition and behavior (<xref rid="B18" ref-type="bibr">Hermle and Kraehenmann, 2017</xref>). In fact, there is consistent evidence that psychedelics, especially during drug peak effects, induce high emotional arousal: &#x0201c;&#x02026;intense, labile, personally meaningful emotionality is uniformly produced, with periodic episodes of overwhelming feeling&#x0201d; (<xref rid="B40" ref-type="bibr">Pahnke et al., 1971</xref>). Even under high-dose drug conditions, most subjects describe their imagery as highly pleasurable and rewarding (&#x0201c;cosmic joy&#x0201d;), coming along with feelings of &#x0201c;boundlessness&#x0201d; and &#x0201c;unity&#x0201d; (&#x0201c;oceanic boundlessness&#x0201d;) (<xref rid="B17" ref-type="bibr">Griffiths et al., 2011</xref>; <xref rid="B53" ref-type="bibr">Studerus et al., 2011</xref>). Moreover, previous factor analytical studies (<xref rid="B52" ref-type="bibr">Studerus et al., 2010</xref>, <xref rid="B53" ref-type="bibr">2011</xref>; <xref rid="B29" ref-type="bibr">Lebedev et al., 2015</xref>) support the view that psychedelics induce altered states of consciousness based on two main factors: visual imagery on the one hand, and emotionally experienced alterations in self-awareness and loss of self-/body-boundaries on the other hand. Taken together, our results are entirely consistent with this view because LSD significantly induced vivid imagery on the VAS subscale, blissful state (positively valenced mood state) and disembodiment on the 5D-ASC subscale (<bold>Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref></bold>).</p><p>Recent behavioral (<xref rid="B21" ref-type="bibr">Kometer et al., 2012</xref>, <xref rid="B22" ref-type="bibr">2013</xref>; <xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>) and neurobiological studies (<xref rid="B29" ref-type="bibr">Lebedev et al., 2015</xref>; <xref rid="B41" ref-type="bibr">Preller et al., 2017</xref>) may help explain why psychedelics are such potent modulators of visual imagery, emotions, and self-/body-awareness. For example, it has been shown that 5-HT2A receptor activation in the brain is a central mechanism underlying psychedelic-induced imagery (<xref rid="B22" ref-type="bibr">Kometer et al., 2013</xref>), positive mood states (<xref rid="B21" ref-type="bibr">Kometer et al., 2012</xref>), and alterations in the sense of self and body (<xref rid="B55" ref-type="bibr">Vollenweider et al., 1998</xref>). Therefore, our results are consistent with this view because ketanserin-pretreatment of LSD completely blocked the observed subjective and behavioral effects of LSD (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold> and <bold>Supplementary Figure <xref ref-type="supplementary-material" rid="SM1">S1</xref></bold>). Given that 5-HT receptors are widely expressed in the human brain (<xref rid="B4" ref-type="bibr">Beliveau et al., 2017</xref>), they have important functions in the regulation of mood states, instinctual drives, sleep, and dreaming (<xref rid="B38" ref-type="bibr">Nichols and Nichols, 2008</xref>; <xref rid="B39" ref-type="bibr">Pace-Schott, 2008</xref>). In fact, we (<xref rid="B25" ref-type="bibr">Kraehenmann et al., 2017</xref>) have recently shown that 5-HT2A receptor activation by LSD induces dreamlike imagery, correlating with LSD-induced loss of self-boundaries and cognitive control. Given that there is a broad phenomenological and neurophysiological overlap between psychedelic states and dreaming (<xref rid="B24" ref-type="bibr">Kraehenmann, 2017</xref>), and given that primary process thinking is the prevalent cognitive mode in dreams (<xref rid="B43" ref-type="bibr">Rapaport, 1950</xref>; <xref rid="B19" ref-type="bibr">Holt, 1956</xref>; <xref rid="B2" ref-type="bibr">Auld et al., 1968</xref>; <xref rid="B45" ref-type="bibr">Shevrin, 1996</xref>; <xref rid="B46" ref-type="bibr">Sloman and Steinberg, 1996</xref>; <xref rid="B6" ref-type="bibr">Brakel et al., 2000</xref>), it is plausible to assume that 5-HT2A receptor activation by psychedelics induces dreamlike imagery which is related to primary process thinking, emotion activation, and alterations in the sense of self and body. This is strongly supported by our results because LSD-induced primary process thinking was positively correlated with LSD-induced cognitive bizarreness, a formal measure of dreaming cognition (<bold>Figure <xref ref-type="fig" rid="F1">1C</xref></bold>), and was related to both LSD-induced blissful state (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>) and disembodiment (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>) on the 5D-ASC. Finally, this is also supported by previous neuroimaging studies (<xref rid="B33" ref-type="bibr">Maquet et al., 1996</xref>; <xref rid="B7" ref-type="bibr">Braun, 1997</xref>; <xref rid="B47" ref-type="bibr">Solms, 2000</xref>; <xref rid="B29" ref-type="bibr">Lebedev et al., 2015</xref>) which found that both psychedelics and rapid-eye movement dreams activate temporal lobe regions, leading to visual imagery and changes in the sense of self and body.</p><p>The close relationship between primary process thinking, dream-like cognitive bizarreness, imagery intensity and emotionality during LSD in conjunction with guided mental imagery relative to guided imagery during placebo implicates that LSD in combination with mental imagery induces inner experiences which are different from those produced by either LSD alone or guided mental imagery alone. Given that mental imagery and dreams establish privileged access to latent relational and emotional schemes (<xref rid="B16" ref-type="bibr">Grenell, 2008</xref>; <xref rid="B23" ref-type="bibr">Kottje-Birnbacher, 2011</xref>), LSD and other classical psychedelics might be beneficially used as add-on pharmacotherapeutics to deepen psychotherapeutic processes (<xref rid="B24" ref-type="bibr">Kraehenmann, 2017</xref>). In fact, early clinical studies between 1950 and 1970 used LSD in a similar way (<xref rid="B51" ref-type="bibr">Strassman, 1995</xref>). <xref rid="B31" ref-type="bibr">Levine and Ludwig (1965)</xref>, for example, showed that the combination of hypnosis and LSD produced more profound alterations in consciousness than either hypnosis or LSD alone. Future clinical studies could test this hypothesis by using a study design with several treatment arms comparing either psychedelics without psychotherapy versus psychedelics in conjunction with psychotherapy versus psychotherapy alone.</p><sec><title>Limitations</title><p>We only assessed primary process thinking during the descending phase of the acute effects of LSD (<xref rid="B10" ref-type="bibr">Dolder et al., 2015</xref>). Therefore, we didn&#x02019;t measure drug peak-effects, which might have yielded different results. Nonetheless, we are confident that peak-effects of LSD on cognition and subjective experience would turn out to be similar, if not even stronger, than the observed effects, given that during drug peak, the effects of LSD were completely blocked by ketanserin, and given that LSD induced more primary process in subjects which had more intense subjective drug effects (<bold>Figures <xref ref-type="fig" rid="F1">1A,B</xref></bold>). However, we did not assess dose-dependency of the effects of LSD on primary process thinking. Given that a recent neuroimaging study (<xref rid="B32" ref-type="bibr">Lewis et al., 2017</xref>) did not find dose-dependent differences between brain activation patterns in the acute psychedelic state, and given that dose-response relationships for psychedelic drug effects are approximately linear (<xref rid="B53" ref-type="bibr">Studerus et al., 2011</xref>), we expect the effects of LSD on primary process thinking to linearly increase with increasing dose.</p></sec></sec><sec><title>Conclusion</title><p>We found that LSD, compared with placebo, enhanced primary process thinking in relation to disembodiment and blissful state. Our results confirm previous studies which showed that psychedelics acutely increase primary process thinking. Furthermore, our results indicate that psychedelic-induced primary process thinking is closely related to 5-HT2A receptor activation and the effects on mood state and sense of self and body. Taken together, we show that psychedelics induce transient, but fundamental changes in consciousness which otherwise are only experienced under psychophysiological conditions where primary process is activated such as in dreams. Finally, the results of this study may help extend current understanding of the cognitive mechanisms underlying psychedelic-induced subjective experience. Future clinical studies may test the hypothesis that therapeutic efficacy is mediated by the psychedelic-induced primary process thinking.</p></sec><sec><title>Author Contributions</title><p>Each of the authors participated in this research by contributing to the conception and design of the study (RK, DP, KP, and FV), study management (RK, KP, TP, ES, and FV) performance of laboratory experiments (RK, KP, and TP) and statistical analysis and interpretation (RK, DP, HA, OB, ES, and FV).</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This study was financially supported by grants from the Heffter Research Institute (1-190413), the Swiss Neuromatrix Foundation (2015-0103), the Usona Institute (2015-2056) and the Swiss National Science Foundation (SNSF, P2ZHP1_161626).</p></fn></fn-group><ack><p>We thank the staff at the Department of Psychiatry Psychotherapy and Psychosomatics for the medical and administrative support.</p></ack><sec sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2017.00814/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2017.00814/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><label>FIGURE S1</label><caption><p>State of consciousness at the time of the mental imagery task. The graph shows the score on each 5D-ASC subscale in each drug condition at time point T3 = 390 min after drug intake. LSD increased the score on all five 5D-ASC subscales. Ketanserin pre-treatment completely blocked all LSD-induced effects (all <italic>p</italic> = n.s.). Asterisks indicate significant differences between LSD and placebo conditions (<sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup><italic>p</italic> &#x0003c; 0.001, Bonferroni-corrected). 5D-ASC, Altered States of Consciousness; Pla, placebo; Ket, ketanserin; LSD, lysergic acid diethylamide.</p></caption><media xlink:href="Image_1.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Image_1.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><label>FIGURE S2</label><caption><p>Mental imagery experience. The graph shows the score on each visual analog subscale (VAS) in each drug condition. LSD increased VAS score for visual vividness and emotional arousal. Ketanserin pre-treatment completely blocked all LSD-induced effects (all <italic>p</italic> = n.s.). Asterisks indicate significant differences between LSD and placebo conditions (<sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup><italic>p</italic> &#x0003c; 0.001, Bonferroni-corrected). Pla, placebo; Ket, ketanserin; LSD, lysergic acid diethylamide.</p></caption><media xlink:href="Image_2.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM4"><media xlink:href="Image_2.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arminjon</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>The four postulates of Freudian unconscious neurocognitive convergences.</article-title>
<source><italic>Front. Psychol.</italic></source>
<volume>2</volume>:<issue>125</issue>. <pub-id pub-id-type="doi">10.3389/fpsyg.2011.00125</pub-id>
<pub-id pub-id-type="pmid">21734896</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auld</surname><given-names>F.</given-names></name><name><surname>Goldenberg</surname><given-names>G. M.</given-names></name><name><surname>Weiss</surname><given-names>J. V.</given-names></name></person-group> (<year>1968</year>). <article-title>Measurement of primary-process thinking in dream reports.</article-title>
<source><italic>J. Pers. Soc. Psychol.</italic></source>
<volume>8</volume>
<fpage>418</fpage>&#x02013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1037/h0025488</pub-id>
<pub-id pub-id-type="pmid">4171430</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>H. L.</given-names></name><name><surname>Langs</surname><given-names>R. J.</given-names></name><name><surname>Holt</surname><given-names>R. R.</given-names></name><name><surname>Goldberger</surname><given-names>L.</given-names></name><name><surname>Klein</surname><given-names>G. S.</given-names></name></person-group> (<year>1972</year>). <source><italic>LSD: Personality and Experience</italic>.</source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Wiley-Interscience</publisher-name>.</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beliveau</surname><given-names>V.</given-names></name><name><surname>Ganz</surname><given-names>M.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Ozenne</surname><given-names>B.</given-names></name><name><surname>H&#x000f8;jgaard</surname><given-names>L.</given-names></name><name><surname>Fisher</surname><given-names>P. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A high-resolution in vivo atlas of the human brain&#x02019;s serotonin system.</article-title>
<source><italic>J. Neurosci.</italic></source>
<volume>37</volume>
<fpage>120</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2830-16.2016</pub-id><pub-id pub-id-type="pmid">28053035</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belser</surname><given-names>A. B.</given-names></name><name><surname>Agin-Liebes</surname><given-names>G.</given-names></name><name><surname>Swift</surname><given-names>T. C.</given-names></name><name><surname>Terrana</surname><given-names>S.</given-names></name><name><surname>Devenot</surname><given-names>N.</given-names></name><name><surname>Friedman</surname><given-names>H. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Patient experiences of psilocybin-assisted psychotherapy. An interpretative phenomenological analysis.</article-title>
<source><italic>J. Hum. Psychol.</italic></source>
<volume>57</volume>
<fpage>354</fpage>&#x02013;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1177/0022167817706884</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brakel</surname><given-names>L. A.</given-names></name><name><surname>Kleinsorge</surname><given-names>S.</given-names></name><name><surname>Snodgrass</surname><given-names>M.</given-names></name><name><surname>Shevrin</surname><given-names>H.</given-names></name></person-group> (<year>2000</year>). <article-title>The primary process and the unconscious: experimental evidence supporting two psychoanalytic presuppositions.</article-title>
<source><italic>Int. J. Psychoanal.</italic></source>
<volume>81(Pt 3)</volume>
<fpage>553</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1516/0020757001599951</pub-id>
<pub-id pub-id-type="pmid">10967775</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>A.</given-names></name></person-group> (<year>1997</year>). <article-title>Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study.</article-title>
<source><italic>Brain</italic></source>
<volume>120</volume>
<fpage>1173</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1093/brain/120.7.1173</pub-id>
<pub-id pub-id-type="pmid">9236630</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>R. L.</given-names></name><name><surname>Erritzoe</surname><given-names>D.</given-names></name><name><surname>Williams</surname><given-names>T.</given-names></name><name><surname>Stone</surname><given-names>J. M.</given-names></name><name><surname>Reed</surname><given-names>L. J.</given-names></name><name><surname>Colasanti</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>109</volume>
<fpage>2138</fpage>&#x02013;<lpage>2143</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1119598109</pub-id>
<pub-id pub-id-type="pmid">22308440</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>R. L.</given-names></name><name><surname>Leech</surname><given-names>R.</given-names></name><name><surname>Hellyer</surname><given-names>P. J.</given-names></name><name><surname>Shanahan</surname><given-names>M.</given-names></name><name><surname>Feilding</surname><given-names>A.</given-names></name><name><surname>Tagliazucchi</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.</article-title>
<source><italic>Front. Hum. Neurosci.</italic></source>
<volume>8</volume>:<issue>20</issue>. <pub-id pub-id-type="doi">10.3389/fnhum.2014.00020</pub-id>
<pub-id pub-id-type="pmid">24550805</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Haschke</surname><given-names>M.</given-names></name><name><surname>Rentsch</surname><given-names>K. M.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Pharmacokinetics and concentration-effect relationship of oral LSD in humans.</article-title>
<source><italic>Int. J. Neuropsychopharmacol.</italic></source>
<volume>19</volume>:<issue>pyv072</issue>. <pub-id pub-id-type="doi">10.1093/ijnp/pyv072</pub-id>
<pub-id pub-id-type="pmid">26108222</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dresler</surname><given-names>M.</given-names></name><name><surname>Eibl</surname><given-names>L.</given-names></name><name><surname>Fischer</surname><given-names>C. F. J.</given-names></name><name><surname>Wehrle</surname><given-names>R.</given-names></name><name><surname>Spoormaker</surname><given-names>V. I.</given-names></name><name><surname>Steiger</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Volitional components of consciousness vary across wakefulness, dreaming and lucid dreaming.</article-title>
<source><italic>Front. Psychol.</italic></source>
<volume>4</volume>:<issue>987</issue>. <pub-id pub-id-type="doi">10.3389/fpsyg.2013.00987</pub-id>
<pub-id pub-id-type="pmid">24427149</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>J. S. B. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Dual-processing accounts of reasoning, judgment, and social cognition.</article-title>
<source><italic>Annu. Rev. Psychol.</italic></source>
<volume>59</volume>
<fpage>255</fpage>&#x02013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.psych.59.103006.093629</pub-id>
<pub-id pub-id-type="pmid">18154502</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Family</surname><given-names>N.</given-names></name><name><surname>Vinson</surname><given-names>D.</given-names></name><name><surname>Vigliocco</surname><given-names>G.</given-names></name><name><surname>Kaelen</surname><given-names>M.</given-names></name><name><surname>Bolstridge</surname><given-names>M.</given-names></name><name><surname>Nutt</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Semantic activation in LSD: evidence from picture naming.</article-title>
<source><italic>Lang. Cogn. Neurosci.</italic></source>
<volume>31</volume>
<fpage>1320</fpage>&#x02013;<lpage>1327</lpage>. <pub-id pub-id-type="doi">10.1080/23273798.2016.1217030</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>E.</given-names></name><name><surname>Stigler</surname><given-names>M.</given-names></name><name><surname>Georg</surname><given-names>H.</given-names></name><name><surname>Fischer</surname><given-names>N.</given-names></name><name><surname>Bumeder</surname><given-names>I.</given-names></name><name><surname>Pokorny</surname><given-names>D.</given-names></name></person-group> (<year>2008</year>). <article-title>Tumor patients in psychodynamic psychotherapy including daydreaming: can imagery enhance primary process and positive emotions?</article-title>
<source><italic>Psychother. Res.</italic></source>
<volume>18</volume>
<fpage>444</fpage>&#x02013;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1080/10503300701832433</pub-id>
<pub-id pub-id-type="pmid">18815996</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasser</surname><given-names>P.</given-names></name><name><surname>Kirchner</surname><given-names>K.</given-names></name><name><surname>Passie</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.</article-title>
<source><italic>J. Psychopharmacol.</italic></source>
<volume>29</volume>
<fpage>57</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1177/0269881114555249</pub-id>
<pub-id pub-id-type="pmid">25389218</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grenell</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Affect integration in dreams and dreaming.</article-title>
<source><italic>J. Am. Psychoanal. Assoc.</italic></source>
<volume>56</volume>
<fpage>223</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1177/0003065108315694</pub-id>
<pub-id pub-id-type="pmid">18430709</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>M. W.</given-names></name><name><surname>Richards</surname><given-names>W. A.</given-names></name><name><surname>Richards</surname><given-names>B. D.</given-names></name><name><surname>McCann</surname><given-names>U.</given-names></name><name><surname>Jesse</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>218</volume>
<fpage>649</fpage>&#x02013;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-011-2358-5</pub-id>
<pub-id pub-id-type="pmid">21674151</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermle</surname><given-names>L.</given-names></name><name><surname>Kraehenmann</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Experimental psychosis research and schizophrenia-similarities and dissimilarities in psychopathology.</article-title>
<source><italic>Curr. Top. Behav. Neurosci.</italic></source>
<pub-id pub-id-type="doi">10.1007/7854_2016_460</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">28444578</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>R. R.</given-names></name></person-group> (<year>1956</year>). <article-title>Gauging primary and secondary processes in Rorschach responses.</article-title>
<source><italic>J. Proj. Tech.</italic></source>
<volume>20</volume>
<fpage>14</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1080/08853126.1956.10380666</pub-id>
<pub-id pub-id-type="pmid">13307476</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>R. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Quantitative research on the primary process: method and findings.</article-title>
<source><italic>J. Am. Psychoanal. Assoc.</italic></source>
<volume>50</volume>
<fpage>457</fpage>&#x02013;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1177/00030651020500021501</pub-id>
<pub-id pub-id-type="pmid">12206540</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kometer</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>Bachmann</surname><given-names>R.</given-names></name><name><surname>Studerus</surname><given-names>E.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2012</year>). <article-title>Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>72</volume>
<fpage>898</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.04.005</pub-id>
<pub-id pub-id-type="pmid">22578254</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kometer</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>J&#x000e4;ncke</surname><given-names>L.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2013</year>). <article-title>Activation of serotonin 2A receptors underlies the psilocybin-induced effects on &#x003b1; oscillations, N170 visual-evoked potentials, and visual hallucinations.</article-title>
<source><italic>J. Neurosci.</italic></source>
<volume>33</volume>
<fpage>10544</fpage>&#x02013;<lpage>10551</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3007-12.2013</pub-id>
<pub-id pub-id-type="pmid">23785166</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kottje-Birnbacher</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Imaginations in psychodynamic psychotherapy.</article-title>
<source><italic>Psychotherapeut</italic></source>
<volume>56</volume>
<fpage>142</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1007/s00278-010-07814</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraehenmann</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Dreams and psychedelics: neurophenomenological comparison and therapeutic implications.</article-title>
<source><italic>Curr. Neuropharmacol.</italic></source>
<volume>15</volume>
<fpage>1032</fpage>&#x02013;<lpage>1042</lpage>. <pub-id pub-id-type="doi">10.2174/1573413713666170619092629</pub-id>
<pub-id pub-id-type="pmid">28625125</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>Pokorny</surname><given-names>D.</given-names></name><name><surname>Vollenweider</surname><given-names>L.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Pokorny</surname><given-names>T.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>234</volume>
<fpage>2031</fpage>&#x02013;<lpage>2046</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-017-4610-0</pub-id>
<pub-id pub-id-type="pmid">28386699</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Scheidegger</surname><given-names>M.</given-names></name><name><surname>Pokorny</surname><given-names>T.</given-names></name><name><surname>Bosch</surname><given-names>O. G.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>78</volume>
<fpage>572</fpage>&#x02013;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.04.010</pub-id>
<pub-id pub-id-type="pmid">24882567</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>Schmidt</surname><given-names>A.</given-names></name><name><surname>Friston</surname><given-names>K.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2016</year>). <article-title>The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.</article-title>
<source><italic>Neuroimage Clin.</italic></source>
<volume>11</volume>
<fpage>53</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2015.08.009</pub-id>
<pub-id pub-id-type="pmid">26909323</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landon</surname><given-names>M.</given-names></name><name><surname>Fischer</surname><given-names>R.</given-names></name></person-group> (<year>1970</year>). <article-title>On similar linguistic structures in creative performance and psilocybin-induced experience.</article-title>
<source><italic>Confin. Psychiatr.</italic></source>
<volume>13</volume>
<fpage>115</fpage>&#x02013;<lpage>138</lpage>. <pub-id pub-id-type="pmid">5478353</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedev</surname><given-names>A. V.</given-names></name><name><surname>L&#x000f6;vd&#x000e9;n</surname><given-names>M.</given-names></name><name><surname>Rosenthal</surname><given-names>G.</given-names></name><name><surname>Feilding</surname><given-names>A.</given-names></name><name><surname>Nutt</surname><given-names>D. J.</given-names></name><name><surname>Carhart-Harris</surname><given-names>R. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin.</article-title>
<source><italic>Hum. Brain Mapp.</italic></source>
<volume>36</volume>
<fpage>3137</fpage>&#x02013;<lpage>3153</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.22833</pub-id>
<pub-id pub-id-type="pmid">26010878</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leuner</surname><given-names>H.</given-names></name></person-group> (<year>1969</year>). <article-title>Guided affective imagery (GAI). A method of intensive psychotherapy.</article-title>
<source><italic>Am. J. Psychother.</italic></source>
<volume>23</volume>
<fpage>4</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="pmid">4180780</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>J.</given-names></name><name><surname>Ludwig</surname><given-names>A.</given-names></name></person-group> (<year>1965</year>). <article-title>Alterations in consciousness produced by combinations of LSD, hypnosis and psychotherapy.</article-title>
<source><italic>Psychopharmacologia</italic></source>
<volume>7</volume>
<fpage>123</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1007/BF00403635</pub-id>
<pub-id pub-id-type="pmid">5830970</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>C. R.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>Michels</surname><given-names>L.</given-names></name><name><surname>Staempfli</surname><given-names>P.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2017</year>). <article-title>Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.</article-title>
<source><italic>Neuroimage</italic></source>
<volume>159</volume>
<fpage>70</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.07.020</pub-id>
<pub-id pub-id-type="pmid">28711736</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maquet</surname><given-names>P.</given-names></name><name><surname>P&#x000e9;ters</surname><given-names>J.</given-names></name><name><surname>Aerts</surname><given-names>J.</given-names></name><name><surname>Delfiore</surname><given-names>G.</given-names></name><name><surname>Degueldre</surname><given-names>C.</given-names></name><name><surname>Luxen</surname><given-names>A.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Functional neuroanatomy of human rapid-eye-movement sleep and dreaming.</article-title>
<source><italic>Nature</italic></source>
<volume>383</volume>
<fpage>163</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/383163a0</pub-id>
<pub-id pub-id-type="pmid">8774879</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martindale</surname><given-names>C.</given-names></name><name><surname>Fischer</surname><given-names>R.</given-names></name></person-group> (<year>1977</year>). <article-title>The effects of psilocybin on primary process content in language.</article-title>
<source><italic>Confin. Psychiatr.</italic></source>
<volume>20</volume>
<fpage>195</fpage>&#x02013;<lpage>202</lpage>. <pub-id pub-id-type="pmid">608346</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montag</surname><given-names>C.</given-names></name><name><surname>Panksepp</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Primary emotional systems and personality: an evolutionary perspective.</article-title>
<source><italic>Front. Psychol.</italic></source>
<volume>8</volume>:<issue>464</issue>. <pub-id pub-id-type="doi">10.3389/fpsyg.2017.00464</pub-id>
<pub-id pub-id-type="pmid">28443039</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natale</surname><given-names>M.</given-names></name><name><surname>Dahlberg</surname><given-names>C. C.</given-names></name><name><surname>Jaffe</surname><given-names>J.</given-names></name></person-group> (<year>1978</year>). <article-title>Effect of psychotomimetics (LSD and dextroamphetamine) on the use of primary- and secondary-process language.</article-title>
<source><italic>J. Consult. Clin. Psychol.</italic></source>
<volume>46</volume>
<fpage>352</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1037/0022-006X.46.2.352</pub-id>
<pub-id pub-id-type="pmid">649815</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natale</surname><given-names>M.</given-names></name><name><surname>Dahlberg</surname><given-names>C. C.</given-names></name><name><surname>Jaffe</surname><given-names>J.</given-names></name></person-group> (<year>1979</year>). <article-title>The effects of LSD-25 and dextroamphetamine on the use of defensive language.</article-title>
<source><italic>J. Clin. Psychol.</italic></source>
<volume>35</volume>
<fpage>250</fpage>&#x02013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1002/1097-4679(197904)35:2&#x0003c;250::AID-JCLP2270350205&#x0003e;3.0.CO;2-G</pub-id>
<pub-id pub-id-type="pmid">457881</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D. E.</given-names></name><name><surname>Nichols</surname><given-names>C. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Serotonin receptors.</article-title>
<source><italic>Chem. Rev.</italic></source>
<volume>108</volume>
<fpage>1614</fpage>&#x02013;<lpage>1641</lpage>. <pub-id pub-id-type="doi">10.1021/cr078224o</pub-id>
<pub-id pub-id-type="pmid">18476671</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pace-Schott</surname><given-names>E. F.</given-names></name></person-group> (<year>2008</year>). <article-title>&#x0201c;Serotonin and dreaming,&#x0201d; in</article-title>
<source><italic>Serotonin and Sleep: Molecular, Functional and Clinical Aspects</italic></source>
<role>eds</role>
<person-group person-group-type="editor"><name><surname>Monti</surname><given-names>J. M.</given-names></name><name><surname>Pandi-Perumal</surname><given-names>S. R.</given-names></name><name><surname>Jacobs</surname><given-names>B. L.</given-names></name><name><surname>Nutt</surname><given-names>D. J.</given-names></name></person-group> (<publisher-loc>Basel</publisher-loc>: <publisher-name>Birkh&#x000e4;user Verlag</publisher-name>) <fpage>307</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-7643-8561-3_12</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahnke</surname><given-names>W. N.</given-names></name><name><surname>Kurland</surname><given-names>A. A.</given-names></name><name><surname>Unger</surname><given-names>S.</given-names></name><name><surname>Savage</surname><given-names>C.</given-names></name><name><surname>Grof</surname><given-names>S.</given-names></name></person-group> (<year>1971</year>). <article-title>The experimental use of psychedelic (LSD) psychotherapy.</article-title>
<source><italic>Int. J. Clin. Pharmacol. Ther. Toxicol.</italic></source>
<volume>4</volume>
<fpage>446</fpage>&#x02013;<lpage>454</lpage>.</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Herdener</surname><given-names>M.</given-names></name><name><surname>Pokorny</surname><given-names>T.</given-names></name><name><surname>Planzer</surname><given-names>A.</given-names></name><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>St&#x000e4;mpfli</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation.</article-title>
<source><italic>Curr. Biol.</italic></source>
<volume>27</volume>
<fpage>451</fpage>&#x02013;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2016.12.030</pub-id>
<pub-id pub-id-type="pmid">28132813</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pribram</surname><given-names>K. H.</given-names></name><name><surname>Gill</surname><given-names>M. M.</given-names></name></person-group> (<year>1976</year>). <source><italic>Freud&#x02019;s &#x02019;Project&#x02019; Reassessed</italic>.</source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Basic Books</publisher-name>.</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapaport</surname><given-names>D.</given-names></name></person-group> (<year>1950</year>). <article-title>On the psycho-analytic theory of thinking.</article-title>
<source><italic>Int. J. Psychoanal.</italic></source>
<volume>31</volume>
<fpage>161</fpage>&#x02013;<lpage>170</lpage>.</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanks</surname><given-names>D. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Learning: from association to cognition.</article-title>
<source><italic>Annu. Rev. Psychol.</italic></source>
<volume>61</volume>
<fpage>273</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.psych.093008.100519</pub-id><pub-id pub-id-type="pmid">19575617</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shevrin</surname><given-names>H.</given-names></name></person-group> (<year>1996</year>). <source><italic>Conscious and Unconscious Processes: Psychodynamic, Cognitive, and Neurophysiological Convergences</italic>.</source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Guilford Press</publisher-name>.</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloman</surname><given-names>S. A.</given-names></name><name><surname>Steinberg</surname><given-names>R. J.</given-names></name></person-group> (<year>1996</year>). <article-title>The empirical case for two systems of reasoning.</article-title>
<source><italic>Psychol. Bull.</italic></source>
<volume>119</volume>
<fpage>3</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1037/0033-2909.119.1.3</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solms</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Dreaming and REM sleep are controlled by different brain mechanisms.</article-title>
<source><italic>Behav. Brain Sci.</italic></source>
<volume>23</volume>
<fpage>843</fpage>&#x02013;<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1017/S0140525X00003988</pub-id>
<pub-id pub-id-type="pmid">11515144</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solms</surname><given-names>M.</given-names></name><name><surname>Panksepp</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>The &#x0201c;Id&#x0201d; knows more than the &#x0201c;Ego&#x0201d; admits: neuropsychoanalytic and primal consciousness perspectives on the interface between affective and cognitive neuroscience.</article-title>
<source><italic>Brain Sci.</italic></source>
<volume>2</volume>
<fpage>147</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.3390/brainsci2020147</pub-id>
<pub-id pub-id-type="pmid">24962770</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>M.</given-names></name><name><surname>Thimm</surname><given-names>M.</given-names></name><name><surname>Hermle</surname><given-names>L.</given-names></name><name><surname>Holzmann</surname><given-names>P.</given-names></name><name><surname>Kovar</surname><given-names>K.-A.</given-names></name><name><surname>Heimann</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Increased activation of indirect semantic associations under psilocybin.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>39</volume>
<fpage>1055</fpage>&#x02013;<lpage>1057</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(95)00418-1</pub-id>
<pub-id pub-id-type="pmid">8780843</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stigler</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Emotions and primary process in guided imagery psychotherapy.</article-title>
<source><italic>Psychother. Res.</italic></source>
<volume>11</volume>
<fpage>415</fpage>&#x02013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1093/ptr/11.4.415</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>R. J.</given-names></name></person-group> (<year>1995</year>). <article-title>Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects.</article-title>
<source><italic>J. Nerv. Ment. Dis.</italic></source>
<volume>183</volume>
<fpage>127</fpage>&#x02013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1097/00005053-199503000-00002</pub-id>
<pub-id pub-id-type="pmid">7891058</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E.</given-names></name><name><surname>Gamma</surname><given-names>A.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2010</year>). <article-title>Psychometric evaluation of the altered states of consciousness rating scale (OAV).</article-title>
<source><italic>PLOS ONE</italic></source>
<volume>5</volume>:<issue>e12412</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0012412</pub-id>
<pub-id pub-id-type="pmid">20824211</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E.</given-names></name><name><surname>Kometer</surname><given-names>M.</given-names></name><name><surname>Hasler</surname><given-names>F.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2011</year>). <article-title>Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.</article-title>
<source><italic>J. Psychopharmacol.</italic></source>
<volume>25</volume>
<fpage>1434</fpage>&#x02013;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1177/0269881110382466</pub-id>
<pub-id pub-id-type="pmid">20855349</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaitl</surname><given-names>D.</given-names></name><name><surname>Birbaumer</surname><given-names>N.</given-names></name><name><surname>Gruzelier</surname><given-names>J.</given-names></name><name><surname>Jamieson</surname><given-names>G. A.</given-names></name><name><surname>Kotchoubey</surname><given-names>B.</given-names></name><name><surname>Kubler</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Psychobiology of altered states of consciousness.</article-title>
<source><italic>Psychol. Bull.</italic></source>
<volume>131</volume>
<fpage>98</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1037/0033-2909.131.1.98</pub-id>
<pub-id pub-id-type="pmid">15631555</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name><name><surname>Vollenweider-Scherpenhuyzen</surname><given-names>M. F.</given-names></name><name><surname>B&#x000e4;bler</surname><given-names>A.</given-names></name><name><surname>Vogel</surname><given-names>H.</given-names></name><name><surname>Hell</surname><given-names>D.</given-names></name></person-group> (<year>1998</year>). <article-title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.</article-title>
<source><italic>Neuroreport</italic></source>
<volume>9</volume>
<fpage>3897</fpage>&#x02013;<lpage>3902</lpage>. <pub-id pub-id-type="doi">10.1097/00001756-199812010-00024</pub-id>
<pub-id pub-id-type="pmid">9875725</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>U.</given-names></name><name><surname>Holzmann</surname><given-names>R.</given-names></name><name><surname>Hobson</surname><given-names>A.</given-names></name><name><surname>Paulus</surname><given-names>W.</given-names></name><name><surname>Koppehele-Gossel</surname><given-names>J.</given-names></name><name><surname>Klimke</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Induction of self awareness in dreams through frontal low current stimulation of gamma activity.</article-title>
<source><italic>Nat. Neurosci.</italic></source>
<volume>17</volume>
<fpage>810</fpage>&#x02013;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3719</pub-id>
<pub-id pub-id-type="pmid">24816141</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>R.</given-names></name><name><surname>Day</surname><given-names>C.</given-names></name><name><surname>Krzanowski</surname><given-names>J.</given-names></name><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>Carhart-Harris</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Patients&#x02019; accounts of increased &#x0201c;connectedness&#x0201d; and &#x0201c;acceptance&#x0201d; after psilocybin for treatment-resistant depression.</article-title>
<source><italic>J. Hum. Psychol.</italic></source>
<volume>6</volume>
<fpage>1</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1177/0022167817709585</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>W.</given-names></name><name><surname>Aronson</surname><given-names>H.</given-names></name></person-group> (<year>1969</year>). <article-title>Application of verbal behavior analysis to the study of psychological defense mechanisms. V. Speech pattern associated with overeating.</article-title>
<source><italic>Arch. Gen. Psychiatry</italic></source>
<volume>21</volume>
<fpage>739</fpage>&#x02013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1969.01740240099012</pub-id>
<pub-id pub-id-type="pmid">4390936</pub-id></mixed-citation></ref></ref-list></back></article>